Unknown PHASE1 INTERVENTIONAL 6-arm NCT02613559

Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration

A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration

Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd

Conditions Neovascular Age-related Macular Degeneration

Interventions TK001

Updated 6 times since 2017 Last updated: Feb 27, 2018 Started: Nov 30, 2015 Primary completion: Jun 30, 2018 Completion: Sep 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Neovascular Age-related Macular Degeneration, this trial is ongoing. The trial is conducted by Jiangsu T-Mab Biopharma Co.,Ltd and has accumulated 6 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Mar 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Mar 2020 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu T-Mab Biopharma Co.,Ltd

Data source: Jiangsu T-Mab Biopharma Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China